Trial is on in Japan
The most important thing I note is that age limit follows >= 5 years and < 18 years rule. 6MWT is not either in the primary or secondary criterion. Secondary criterion is tracking "Detection of exon53 skipped mRNA of dystrophin"
FDA needs to move beyond clinical measures.